A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors.

Disease Sites:

Cervical, Gynecologic, Ovarian, Prostate, Urologic, Uterine

Staging:

Phase I

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

CTIM-76

Principal Investigator(s):

Crispens, Marta

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

12-31-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTGYN24135P

National Clinical Trial ID:

NCT06515613

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available